Clinical trials: Metastatic Esophageal Cancer
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
GastroEsophageal Cancer
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a beneficial contribution to current treatment paradigms since preclinical data suggest that lapatinib alone can decrease TS mRNA and is…
- Trial name
- GastroLap (NCT01145404)
- Testing
- Lapatinib, Lapatinib plus capecitabine
- Where
- 16 sites in Germany
- Volunteers
- 76 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Esophageal Cancer
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the…
- Trial name
- NCT04616040
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 1,030 people
- Sponsor
- Peking University
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Esophagogastric Cancer, HER2-Negative
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer.
- Trial name
- NCT04757363
- Testing
- regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or…
- Trial name
- NCT07621601
- Testing
- HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel
- Volunteers
- 494 people
- Sponsor
- Hansoh BioMedical R&D Company
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery.
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06324357
- Testing
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine
- Where
- 104 sites in United States, Belgium and 8 more
- Volunteers
- 910 people
- Sponsor
- Boehringer Ingelheim
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Esophageal Cancer
Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer
The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.
- Trial name
- NCT00154700
- Testing
- Paclitaxel,Cisplatin,5-Fu,Folic Acid
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Epiphora
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
- Trial name
- NCT00824811
- Testing
- Cyclosporine Eye Drops (Restasis), Lubricant Eye Drops (Refresh Endura™), Fluorometholone Eye Drops (FML Forte®)
- Sponsor
- M.D. Anderson Cancer Center
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Squamous Cell Carcinoma of Esophagus
Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
Interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("Discontinuation design ")of patients with metastatic oesophageal cancer of…
- Trial name
- E-DIS (NCT01248299)
- Testing
- FU-CDDP, LV5FU2-CDDP, FOLFOX
- Where
- 17 sites in France
- Volunteers
- 105 people
- Sponsor
- Centre Oscar Lambret
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- SCR-ESCC-01 (NCT05978193)
- Testing
- LDRT+CFRT, Immunotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche